title: Making the next steps in psoriatic arthritis management: current status and future directions.
abstract: Psoriatic arthritis (PsA) is a chronic inflammatory condition with articular and extra-articular manifestations: peripheral arthritis, axial disease, enthesitis, dactylitis, and skin and nail disease. It is associated with cardiovascular comorbidities. It is now recognized as a new entity, different from rheumatoid arthritis and other spondyloarthritis in terms of clinical manifestations, pathogenesis, and response to therapies. Anti-tumor necrosis factors (anti-TNFs) have demonstrated clinical efficacies exceeding that of conventional disease modifying antirheumatic drugs (DMARDs). The current treatment paradigms recommend early diagnosis and treatment, and a strategic and target orientated approach, aiming at a low disease activity status. New understanding in the immunopathogenesis of PsA has led to new treatment targets. This review addresses the evidence of current treatment for each of the domains as an aid to the clinician managing these patients in the clinic. Some new therapeutic targets are presented. We highlight the importance of development and validation in outcome measures, including that of composite scores that capture various disease domains that will facilitate future clinical trials to inform the best treatment.
authors.affiliation: Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.
authors.forename: Diviya
authors.initials: D
authors.lastname: Sritheran
authors.affiliation: Department of Rheumatology and Immunology, Singapore General Hospital, he Academia, Level 4, 20 College Road, 169856, Singapore and Duke-NUS Graduate Medical School, Singapore.
authors.forename: Ying Ying
authors.initials: YY
authors.lastname: Leung
keywords: disease modifying antirheumatic drug; psoriatic arthritis; treatment; tumor necrosis factor inhibitors